X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA CIPLA NATCO PHARMA/
CIPLA
 
P/E (TTM) x 33.8 44.1 76.8% View Chart
P/BV x 17.2 3.6 474.4% View Chart
Dividend Yield % 0.7 0.4 187.9%  

Financials

 NATCO PHARMA   CIPLA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
CIPLA
Mar-17
NATCO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs877622 141.0%   
Low Rs424458 92.4%   
Sales per share (Unadj.) Rs223.4181.9 122.9%  
Earnings per share (Unadj.) Rs31.112.9 241.4%  
Cash flow per share (Unadj.) Rs40.329.3 137.4%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.80.4 207.7%  
Book value per share (Unadj.) Rs219.5155.7 141.0%  
Shares outstanding (eoy) m33.07804.51 4.1%   
Bonus/Rights/Conversions PAESOP-  
Price / Sales ratio x2.93.0 98.0%   
Avg P/E ratio x20.942.0 49.9%  
P/CF ratio (eoy) x16.118.4 87.6%  
Price / Book Value ratio x3.03.5 85.4%  
Dividend payout %16.115.5 103.6%   
Avg Mkt Cap Rs m21,504434,516 4.9%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m1,12826,338 4.3%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m7,389146,302 5.1%  
Other income Rs m1672,287 7.3%   
Total revenues Rs m7,556148,589 5.1%   
Gross profit Rs m1,79324,758 7.2%  
Depreciation Rs m30413,229 2.3%   
Interest Rs m3661,594 23.0%   
Profit before tax Rs m1,29012,222 10.6%   
Minority Interest Rs m460-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3091,798 17.2%   
Profit after tax Rs m1,02710,354 9.9%  
Gross profit margin %24.316.9 143.4%  
Effective tax rate %23.914.7 162.7%   
Net profit margin %13.97.1 196.5%  
BALANCE SHEET DATA
Current assets Rs m3,68187,370 4.2%   
Current liabilities Rs m3,12333,081 9.4%   
Net working cap to sales %7.637.1 20.4%  
Current ratio x1.22.6 44.6%  
Inventory Days Days8987 102.9%  
Debtors Days Days5962 94.2%  
Net fixed assets Rs m7,685111,567 6.9%   
Share capital Rs m3311,609 20.6%   
"Free" reserves Rs m6,670123,645 5.4%   
Net worth Rs m7,259125,254 5.8%   
Long term debt Rs m95536,454 2.6%   
Total assets Rs m11,957209,532 5.7%  
Interest coverage x4.58.7 52.2%   
Debt to equity ratio x0.10.3 45.2%  
Sales to assets ratio x0.60.7 88.5%   
Return on assets %11.75.7 204.4%  
Return on equity %14.28.3 171.2%  
Return on capital %20.78.5 243.8%  
Exports to sales %39.434.2 115.0%   
Imports to sales %5.78.3 68.3%   
Exports (fob) Rs m2,90850,050 5.8%   
Imports (cif) Rs m42112,203 3.5%   
Fx inflow Rs m3,44551,066 6.7%   
Fx outflow Rs m70317,678 4.0%   
Net fx Rs m2,74333,388 8.2%   
CASH FLOW
From Operations Rs m1,44023,824 6.0%  
From Investments Rs m-1,089-13,127 8.3%  
From Financial Activity Rs m-353-13,239 2.7%  
Net Cashflow Rs m-1-2,478 0.1%  

Share Holding

Indian Promoters % 52.0 16.0 325.3%  
Foreign collaborators % 1.5 20.8 7.1%  
Indian inst/Mut Fund % 7.8 12.2 64.3%  
FIIs % 16.6 23.7 70.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 26.0 26.2 99.2%  
Shareholders   25,395 161,166 15.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS